Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) is an interesting case. In recent times, the stock price has been under a lot of scrutiny from the unwanted results of some of its clinical trials. Over the past year, the stockI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation ...

A pundit at an influential U.S. bank is quite bullish on the company's future.An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (SRRK 6.05%) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on a trading day when the benchmark S&P 500 (^GSPC -0.28%) sagged by 0.3%. A rock of a stockWell before market open, Tazeen Ahmad of Bank of America Securities launched her tracking of Scholar Rock. The reason the market reacted so stron ...

Core Insights - Zenas BioPharma, Inc. has entered into a licensing agreement with InnoCare, valued at approximately $2 billion, granting Zenas rights to the global market [1] Company Overview - Zenas BioPharma focuses on biotechnology innovations, particularly in drug development, leveraging scientific expertise to identify promising companies and therapies [1] Market Implications - The licensing deal is expected to enhance Zenas's market position and expand its portfolio in the biotechnology sector, potentially leading to significant financial returns [1]

STOCKHOLM (Reuters) -Novo Nordisk (NVO) said on Thursday it would buy U.S.-based Akero Therapeutics (AKRO) for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth. Shares of Akero jumped more than 18% in premarket trading, while Novo's Denmark-listed shares were down nearly 2%. The deal underscores new Novo Nordisk CEO Mike Doustdar's efforts to revive sales growth and fend off intense competition from U.S. riv ...

One pundit believes this is a clinical-stage company well worth watching.Highly specialized biotech CG Oncology (CGON 7.13%) was the subject of a new research report Wednesday, and its bullish tone helped lift the company's share price. This improved by more than 7% on the day, easily beating the 0.6% advance of the bellwether S&P 500 (^GSPC 0.58%). A biotech with a tight focusThat publication marked the initiation of coverage on CG Oncology stock by veteran researcher Guggenheim, in the person of prognosti ...

Novo Nordisk ( NVO ) stock has had quite a few ups and downs since Liberation Day, and we haven't quite seen the same recovery as other biopharma stocks since. Year to date, the S&P and EliI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges b ...

The market is sleeping on these stocks, but you don't have to.Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good news is that this often creates opportunities for astute investors to pick up shares of great companies with excellent prospects on the dip.And that's precisely what we have with Novo Nordisk (NVO 1.59%) and Vertex Pharmaceuticals (VRTX -1.40%), two le ...

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]

Key Points Nuvation Bio enrolled the first patient in a late-stage study of Ibtrozi. The bigger story, though, was a Wall Street analyst's initiation of coverage on the stock. 10 stocks we like better than Nuvation Bio › Shares of Nuvation Bio (NYSE: NUVB) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker. Nuvation Bio announced on Tuesday morning that it has enrolled the first patient in its phase 3 cl ...

Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.Eupr ...